This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Tawfik A. Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(11). 2015
PSA screening is associated with significant costs to the health care system when the cost of the PSA test itself is considered in addition to the costs of diagnosis, staging, and treatment of screen-detected PCs.
Subject indexing assigned by CRD
Cost-Benefit Analysis; Early Detection of Cancers; Male; Mass Screening; Prostate-Specific Antigen; Prostatic Neoplasms
Country of organisation
An English language summary is available.
Address for correspondence
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca
Date abstract record published